New antibody boosts hope for cure in blood disorders
NCT ID NCT05357482
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 34 times
Summary
This study tests whether adding a new antibody drug (briquilimab, JSP191) to a standard blood stem cell transplant can help more people with sickle cell disease or beta-thalassemia achieve a full donor cell takeover, potentially curing their condition. About 40 participants aged 13 and older will receive the transplant and be monitored for one year. The goal is to improve transplant success and reduce complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.